Long-Term Outcome Analysis of Permanent Prostate Brachytherapy Using Patient Reported Outcomes: A Critical Self Assessment from a Single Institution Experience

Peter J. Rossi,Yuefang Wang,Peter Nieh,Tomi Ogunleye,Elizabeth Butker,Ashesh B. Jani,Tian Liu

DOI: https://doi.org/10.1016/j.brachy.2014.02.407

IF: 2.441

2014-01-01

Brachytherapy

Abstract:Reporting outcomes in cancer is undeniably important for providers and patients. Although permanent prostate implant (PPI) has been established as a standard treatment for men with prostate cancer, current scrutiny of PPI programs and a decline in the use of this modality for men with prostate cancer make starting a new program onerous. The purpose of this study is to critically evaluate the long term outcome of patients treated with PPI in a program started by a physician with no prior experience. This report concerns the first 111 patients treated with PPI for prostate cancer by a single provider, a new graduate initiating a new program. PPI alone was used for patient with low risk and favorable intermediate risk disease. External radiotherapy combined (Combo) with PPI was used for patients with select higher risk disease. Iodine 125 was used exclusively when the program began in 2006 and Pd 103 was added later. A stranded source/preoperative technique was used initially and real time optimization was implemented in 2010. With IRB approval, patients were assessed at baseline and at 6 month interval for disease control and quality-of-life outcomes using self-assessment surveys (EPIC). Pre treatment and treatment related variables were analyzed for association with outcome and toxicity. T test and chi square test were used for statistical comparisons. The median followup of the 111 consecutively treated subjects is 51 months (range 10-84). See table 1 for patient/treatment characteristics. There have been 3 biochemical failures, no prostate cancer death and 3 deaths from other causes. Dose quality was similar regardless of isotope or technique. For instance, median V100(%)/D90(%)/RV100(cc) for pre operative technique was 92%/107%/0.1cc and for real time optimization was 92%/109%/0.2% (p=NS). The most common side effect was a change in sexual function; only 26% of men at baseline reported a small/moderate/big problem with sexual function while at followup, this increased to 70%. The biggest observed change was an increase in sexual problems described as moderate or big (26% at baseline and 60% at long-term followup). Issues with sexual function were associated with intermediate and high risk disease (p=0.04), but it was not associated with treatment choice (PPI alone vs Combo (p=0.2)) or isotope choice (I-125 vs P-103 (P=0.1)). Gastrointestinal (GI) toxicity was increased in patient who received combo; the incidence of Grade 2 events observed with PPI alone was 1.3% versus 5% with combo (p=0.05). In this single institution experience of 111 men receiving PPI, we observed satisfactory long-term outcomes. A PPI program was started from scratch, the outcomes are comparable to most contemporary studies, and areas for improvement have been identified. PPI alone was associated with less GI toxicity than combo treatment in this cohort. Problems with sexual function after PPI remain a big issue for our treated men. We are investigating preventions and interventions to address the high incidence of sexual side effects from PPI.Tabled 1Total Patient Number111Average Age64.4 ± 6.8T StageT1c87T2a19T2b5PSA≤109610-2012>203GS6617458-106IsotopeI-12547Pd-10364Risk GroupLow56Intermediate48High7ADT Prior to17RTModalityMono-RT76Combined-RT35 Open table in a new tab